What is Thymosin Alpha-1?
Thymosin Alpha-1 (TA1) is one of 40 peptides that can be extracted from Thymosin fraction 5. Thymosin Alfa-1 is a biologically active peptide derived from Prothymosin-alpha, a highly acidic protein, a polypeptide made up of 113 amino acids and encoded by the PTMA gene.
This part of the PTMA gene – Prothymosin Alpha was discovered in the 1960s in research of active thymus substances and was the first to be completely synthesised and split into sequences. Thymosin Alpha 1 is made up of 28 amino acid chains and its task is restoration of the immune system. This allows the body to better protect itself from diseases. TA1 is considered the main component of Thymosin Fraction-5, which restores immunity.
Research has shown that it increases cellular immunity of the human immune system. Its effect on immunity allowed a subsequent use for the treatment of viral infections, including hepatitis B and C.
Thymosines were discovered in the 1960s as scientists sought to find, categorise and study biologically active substances released by the thymus. Studies have shown that some thymosin isolates restored immune function and were collectively referred to as Thymosin Fraction-5.
Based on the studies, thymosines were divided into alpha, beta and gamma fractions by means of their electric fields. Recent studies on thymosines have shown that thymosin beta-1 is ubiquitin. The studies have also shown that thymosines can also be produced by cells outside the thymus gland – the place where immune cells (in Latin Thymus) are produced.
Thymosin Alpha-1 has been tested since 1985 in a number of clinical trials in more than 3,000 patients aged 12 months to 101 years. Some of the many diseases that have been studied in connection with the effects of Thymosin Alpha-1 include seasonal allergies, fungal infections, cirrhosis, chronic obstructive pulmonary disease and multiple sclerosis. Many scientists believe that there are hitherto unrecognised medicinal effects of this substance in diseases such as septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, tuberculosis, severe acute respiratory syndrome and pulmonary infection in seriously ill patients.
How does the Thymosin Alpha 1 peptide work?
TA1 is a synthetic polypeptide. The drug is in phase III studies for the treatment of hepatitis C and in phase II studies for hepatitis B. It can also be used to treat malignant melanoma, hepatocellular carcinoma and drug-resistant tuberculosis. TA1 modulates the immune system by strengthening the function of T-cells. Thymosin Alpha 1 can affect thymocytes by stimulating their division or by converting them into active T-lymphocytes. It is quickly absorbed and reaches maximum serum concentrations within two hours. Blood levels return to baseline within 24 hours, and the half-life in serum is approximately 2 hours.
Thymosin alpha-1 partially reconstitutes the cell part of the immune system by increasing the number of T-cell formations in patients with thymus dysfunction.
Ta1 is part of the family of proteins that provide natural immunity; stimulation by one or more TLR by TLR agonists may increase the adaptive immune response, which is crucial for metabolism. Seven different studies have shown that administration of Ta1 significantly increased the production of vaccination antibodies.
Thymosin Alpha 1 also reduces mortality from severe case of Coronavirus-19 by restoring lymphocytopenia and restoring depleted T lymphocytes. Thymosin alfa 1 (Ta1) has been used for many years in the treatment of viral infections as an immune response modifier.
There are no side effects
Thymosin Alfa 1 is naturally extracted from the body and therefore has no side effects or unwanted side effects in combination with other drugs. If taken in the form of an injection, a sterile needle needs to be used to prevent an adverse reaction. Even so, there may be a feeling of itching or increased sensitivity at the injection site.
Suitable recipients of Thymosin Alpha
The fastest and most effective way to take Thymosin Alpha-1 is by injection. By pinching some skin in a place with enough subcutaneous fat, such as the abdomen, the needle is injected just below the skin. The frequency of the injections should be once a day up to three times a week. Taking Thymosin Alfa-1 is suitable for anyone, since a stronger immune system is an essential protection against common diseases such as colds, flu and other diseases.
Medical studies indicate that it is also useful as immunity support in case of COVID-19. People taking Thymosin Alfa-1 are much less likely to become infected even when exposed to the virus. Several recent studies have shown that TA1 is one of the best ways to protect your body from COVID. It is beneficial to people who have immunity dysfunctions or a B or C type hepatitis, HIV, some types of cancer, tumours or a severe case of sepsis.
It is also part of a thymic hormone drug, Zadaxin.
Thymosin Alpha 1 dosage
When peptides are formed, they tend to break down into a crystalline form, also known as a lipolyzed form. This allows safer transport of peptides in the body, since they are more stable. This means that to re-create them, bacteriostatic or sterile water is required. Depending on how much fluid is used to reconstitute the peptide, the dosage of the amount drawn in the syringe will change.
The average dose of Thymosin Alpha 1 is 1.6 milligrams twice a week. This means that in 10 milligrams of vial reconstituted with 1 millilitre of bacteriostatic water, the substance is to be drawn up to the 8. line on an insulin syringe to obtain a correct dose. The amount of fluid used to reconstitute the peptide will determine what volume of substance will be drawn into the syringe. In other words, if the amount of liquid is doubled to 2 ml, the substance will be drawn up to the 16. line, etc.
This product is for research purposes only.
See more Arcas Nutrition peptides HERE